ImmunityBio Inc
:NK 4:00:00 PM EDT
Officer Changes, Mergers / Acquisitions
Immunitybio And Nantkwest To Merge, Creating A Leading Immunotherapy And Cell Therapy Company
Published: 12/21/2020 11:36 GMT
(NK) - Press Release - Immunitybio and Nantkwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company.
Nantkwest Inc - Immunitybio Shareholders Will Receive a Fixed Exchange Ratio of 0.8190 Shares of Nantkwest for Each Share of Immunitybio Owned.
Nantkwest Inc - Immunitybio Shareholders Will Own Approximately 72% of Combined Company.
Nantkwest Inc - Richard Adcock Will Become CEO of Combined Company.
Nantkwest Inc - Soon-shiong Will Serve As Executive Chairman of Board.
Nantkwest Inc - Immunitybio Shareholders Will Receive a Fixed Exchange Ratio of 0.8190 Shares of Nantkwest for Each Share of Immunitybio Owned.
Nantkwest Inc - Immunitybio Shareholders Will Own Approximately 72% of Combined Company.
Nantkwest Inc - Richard Adcock Will Become CEO of Combined Company.
Nantkwest Inc - Soon-shiong Will Serve As Executive Chairman of Board.